Next-Generation Sequencing of Disseminated Tumor Cells by Elen K. Møller et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 31 December 2013
doi: 10.3389/fonc.2013.00320
Next-generation sequencing of disseminated tumor cells
Elen K. Møller 1,2‡, Parveen Kumar 3‡,ThierryVoet 3,4, April Peterson5, PeterVan Loo6,7, Randi R. Mathiesen1,8,
Renathe Fjelldal 9, Jason Grundstad 5, Elin Borgen9, Lars O. Baumbusch1,2†, Bjørn Naume2,8,10,
Anne-Lise Børresen-Dale1,2*, Kevin P.White5, Silje Nord 1,2 andVessela N. Kristensen1,2,11
1 Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
2 K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3 Centre for Human Genetics, Department of Human Genetics, University Hospital Leuven, KU Leuven, Leuven, Belgium
4 Single-Cell Genomics Centre,WellcomeTrust Sanger Institute, Hinxton, UK
5 Institute for Genomics and Systems Biology, Department of Human Genetics, The University of Chicago, Chicago, IL, USA
6 Cancer Genome Project, WellcomeTrust Sanger Institute, Hinxton, UK
7 Department of Human Genetics, VIB and KU Leuven, Leuven, Belgium
8 Department of Oncology, Division of Surgery and Cancer Medicine, Oslo University Hospital Radiumhospitalet, Oslo, Norway
9 Department of Pathology, Oslo University Hospital Radiumhospitalet, Oslo, Norway
10 Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
11 Department of Clinical Molecular Biology (EpiGen), Medical Division, Akershus University Hospital, Lørenskog, Norway
Edited by:
Vanessa Almendro, Dana Farber
Cancer Institute, USA
Reviewed by:
Luisa Lanfrancone, European Institute
of Oncology, Italy
Vanessa Almendro, Dana Farber
Cancer Institute, USA
*Correspondence:
Anne-Lise Børresen-Dale,
Department of Genetics, Institute for
Cancer Research, Oslo University
Hospital Radiumhospitalet, Postboks
4953, Nydalen, Oslo 0424, Norway
e-mail: a.l.borresen-dale@
medisin.uio.no
†Present address:
Lars O. Baumbusch, Department of
Pediatric Research,Women and
Children’s Division, Oslo University
Hospital Rikshospitalet, Oslo, Norway
‡Elen K. Møller and Parveen Kumar
have contributed equally to this work.
Disseminated tumor cells (DTCs) detected in the bone marrow have been shown as
an independent prognostic factor for women with breast cancer. However, the mecha-
nisms behind the tumor cell dissemination are still unclear and more detailed knowledge
is needed to fully understand why some cells remain dormant and others metastasize.
Sequencing of single cells has opened for the possibility to dissect the genetic content
of subclones of a primary tumor, as well as DTCs. Previous studies of genetic changes
in DTCs have employed single-cell array comparative genomic hybridization which pro-
vides information about larger aberrations. To date, next-generation sequencing provides
the possibility to discover new, smaller, and copy neutral genetic changes. In this study,
we performed whole-genome amplification and subsequently next-generation sequenc-
ing to analyze DTCs from two breast cancer patients. We compared copy-number profiles
of the DTCs and the corresponding primary tumor generated from sequencing and SNP-
comparative genomic hybridization (CGH) data, respectively. While one tumor revealed
mostly whole-arm gains and losses, the other had more complex alterations, as well as
subclonal amplification and deletions. Whole-arm gains or losses in the primary tumor
were in general also observed in the corresponding DTC. Both primary tumors showed
amplification of chromosome 1q and deletion of parts of chromosome 16q, which was
recaptured in the corresponding DTCs. Interestingly, clear differences were also observed,
indicating that the DTC underwent further evolution at the copy-number level. This study
provides a proof-of-principle for sequencing of DTCs and correlation with primary copy-
number profiles.The analyses allow insight into tumor cell dissemination and show ongoing
copy-number evolution in DTCs compared to the primary tumors.
Keywords: single tumor cell sequencing, disseminating tumor cells, circulating tumor cells, tumor heterogeneity,
clonal evolution
INTRODUCTION
Tumor cell dissemination to distant sites is one prerequisite for
metastasis, and the presence of single tumor cells in bone mar-
row (BM) (disseminated tumor cells, DTCs) and/or circulating
tumor cells (CTCs) in blood, has been shown to be a strong
prognostic factor in early breast cancer (1–4). The entire process
behind tumor progression and development of metastasis is not
fully understood. The release of tumor cells from the primary
site to the circulation (5) and gain of additional genetic alter-
ations has by some investigators been postulated to occur in
parallel to the formation of the primary tumor. Others believe
they descend from certain subclones present in a heterogeneous
primary tumor. These two models are referred to as parallel and
step-wise progression, respectively (6). There is growing evidence
for primary tumor heterogeneity, based both on phenotypical and
genotypical differences within the tumor (7–9). When comparing
the expression of single genes and proteins between primary tumor
and metastatic tissue, disparities have been observed in a subset of
the samples (10), becoming even more evident when performing
genome-wide analyses (11, 12). Differences between the primary
tumor and overt metastases may be caused by further tumor evolu-
tion at distant sites and/or different disseminating and metastatic
potential between subclones in a heterogeneous primary tumor.
Adjuvant systemic treatment after primary surgery of breast
cancer has improved survival markedly over the last decade (13).
However, depending on the cancer subtype, the systemic treatment
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does not cure more than 30–60% of the patients with minimal
residual disease (14). This may be caused by general resistance to
the treatment administered or treatment insufficiency because of
treatment-related differences between the crude primary tumor
and the DTCs. Analysis of genomic changes at the single-cell level
may reveal the underlying composition of the cells that have dis-
seminated, and from which subclone they originate (7). In this
respect, the acquisition of methods for in-depth single-cell analy-
sis is important to obtain the necessary knowledge of the tumor
cell dissemination and metastatic process and in turn, it is crucial
for targeted treatment of DTCs.
Today’s sequencing techniques can discover all classes of DNA
mutation, but do not allow us to directly study the small amounts
of DNA obtained from a single cell. Therefore whole-genome
amplification (WGA) is required to enable the analysis of a single
cell’s genome. Importantly various artifacts created during WGA
may affect downstream detection of reliable genuine genetic vari-
ants. WGA of single-cell DNA can be based either on multiple
displacement amplification (MDA), polymerase chain reaction
(PCR), or methods combining principles of both. Furthermore,
the amount and nature of artifacts can vary significantly between
different WGA methods. Although pure MDA-based WGA meth-
ods appear to be the method of choice for typing single-nucleotide
variants (15–19), WGA-methods involving PCR seem to preserve
single-cell DNA-copy number changes more accurately during
the amplification process and may be used for single-nucleotide
variant detection as well (20–22).
Previously genomic rearrangements in DTCs have been stud-
ied using low resolution technologies, e.g., comparative genomic
hybridization (CGH), array comparative genomic hybridization
(aCGH), and fluorescence in situ hybridization (FISH) (23–25).
Analysis of copy number changes in DTCs by aCGH only allows
us to identify genomic modifications larger than two megabases
due to the difficulty in interpreting the inherently noisy single-cell
WGA data and the limited array-resolution genome wide (25). In
contrast, sequencing technology enables us to study copy-number
alterations in more detail by focal read depth analyses (7, 26) and
to compute a digital B-allele frequency (BAF) (22). The latter can
not only corroborate DNA-copy number changes, but also reveal
copy neutral loss of heterozygosity (cnLOH).
The aim of this study was to investigate whether whole-genome
sequencing of WGA DNA obtained from single (micromanipu-
lated) DTCs could provide reliable data of genetic changes, as
well as to provide a proof of principle that it is possible to com-
pare the copy-number landscape of a DTC to that of its primary
tumor. In addition, we wanted to see if we could recapitulate the
copy number changes from previous aCGH results, and in even
greater detail gain information of the genetic alterations in a single
cell.
MATERIALS AND METHODS
PATIENT MATERIAL
Bone marrow and primary tumor were analyzed from two local-
ized breast cancer patients included in the Oslo Micrometastasis
(MicMa) project, classified as pT2pN0M0 and pT2pN3M0 (3).
Both patients had estrogen receptor (ER) and progesterone recep-
tor (PR) positive tumors, both were human epidermal growth
factor receptor 2 (Her2) negative. Tumors were fresh frozen at
−80°C and DNA was extracted using an ABI 341 Nucleic Acid
Purification System (Applied Biosystems, Carlsbad, CA, USA)
according to the manufacturer’s protocol. BM was aspirated
from posterior iliac crests (bilaterally) at the time of surgery,
followed by isolation of mononuclear cells and by preparation
of cytospins for detection of DTCs by immunocytochemistry
(ICC) (25).
DETECTION, MICROMANIPULATION, AND DNA AMPLIFICATION OF
DTCs
All methods are described in detail in Mathiesen et al. (25). In
brief, detection of DTCs was performed by ICC staining of the
cytospins, followed by isolation of single tumor cells by micro-
manipulation (see flow chart in Figure 1). The cell was deposited
in an optical lid closed with an Eppendorf PCR tube, centrifuged
for 10 s, and stored at −20°C. Amplification of DNA for the DTC
was performed using GenomePlex® Single-Cell Whole-Genome
Amplification Kit (Sigma-Aldrich, St. Louis, MO, USA). Cell lysis,
fragmentation, and library preparation were all done according
to the manufacturer’s instructions. DNA amplification was per-
formed using Sigma-Aldrich amplification master mix and Tita-
nium Taq DNA polymerase (BD Biosciences Clontech, Heidelberg,
Germany).
ARRAY COMPARATIVE GENOMIC HYBRIDIZATION OF DTCs
Agilent’s Human Genome 244k CGH microarray (Agilent Tech-
nologies, Santa Clara, CA, USA) was used to detect copy-number
alterations in WGA DNA from the DTCs. Scanned microarrays
were preprocessed and linear normalized using Feature Extrac-
tion (Agilent Technologies, Santa Clara, CA, USA) (GEO accession
number GSE27574). The piecewise constant fitting (PCF) algo-
rithm was used to detect chromosomal gains and losses (minimum
amount of probes for segments, kmin, was set to 25 and the penalty
parameter, γ, was set to 60) (27). To avoid outliers, a lowest
detectable value was set and lowest limit on a log2 scale was set to
−2. The zero line was subsequently redefined to give an average
value of 0 across all chromosomes. The procedure is thoroughly
described in Mathiesen et al. (25). Additional GC-correction of
the data was executed here.
WHOLE-GENOME SEQUENCING LIBRARY PREPARATION OF DTCs
Whole-genome amplification DNA (1µg) was sheared using the
S220 Focused-ultrasonicator (Covaris, Woburn, MA, USA) fol-
lowed by end repair using the End-It™ DNA End-Repair Kit
(Epicenter, Madison, WI, USA) (Figure 1). The end-repair mas-
ter mix was made as specified by the manufacturer, mixed with
sheared DNA, and incubated at room temperature for 45 min.
Subsequently each sample underwent A-base addition using an
A-addition master mix and incubated at 37°C for 30 min. The
A-addition master mix consisted of 5µl 10× NEBuffer 2 (New
England Biolabs, Ipswich, MA, USA), 10µl dATP (1 mM) (Sigma-
Aldrich, MO, USA), and 3µl Klenow [3′→ 5′ exo-] (Thermo
Scientific). Following A-base addition, adaptors were ligated onto
the DNA fragments by an adaptor ligation master mix and each
sample was incubated at 16°C for 20 min. Adaptor ligation master
mix was made out of 5µl 10× T4 Ligase Buffer (New England
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FIGURE 1 | Flow chart describing the workflow from collection and detection of the DTC, to library preparation and data analyses.
Biolabs, Ipswich, MA, USA), 5µl adaptor (50µM), and 2µl T4
DNA Ligase (2000 U/µl) (New England Biolabs, Ipswich, MA,
USA) to each sample. After adaptor ligation the sample libraries
were PCR-amplified for 12 cycles. Amplification master mix con-
sisted of 2.5µl universal primer, 2.5µl index primer, and 250µl
2× iProof High-Fidelity Master Mix (Bio-Rad Laboratories, Her-
cules, CA, USA). The amplification master mix (255µl) and MQ
water was added to 125 ng of the template to a total volume of
500µl, spread across five wells at a reaction volume of 100µl. After
each step described above, samples were column cleaned using the
QIAquick PCR Purification Kit (Qiagen, Valencia, CA, USA). Fol-
lowing amplification, library quality assessment was done using
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Further
cleaning was performed using Agencourt AMPure XP (Beckman
Coulter, Brea, CA, USA). Samples were sequenced on HiSeq 2000
(Illumina, San Diego, CA, USA) with half a sequencing lane, over
two lanes, to a total of one lane per sample. Sequencing data can
be obtained by contacting the authors.
MAPPING OF DTC-SEQUENCES
Whole-genome amplification-adapter sequence may contaminate
single-cell sequencing reads. Hence, the sequencing reads were
first investigated for recurrent bases at each position across the
reads. All reads were trimmed by 32 bases to remove WGA-
adapter sequence contamination, and were subsequently aligned
to GRCh37 human reference genome using BWA (28). The result-
ing BAM files were further processed by removal of PCR duplicates
and genomic coverage was calculated using Picard (http://picard.
sourceforge.net/) and Bedtools (29) respectively (Figure 1).
COPY-NUMBER ANALYSIS AND SNP BAF-TYPING OF SINGLE DTCs
Copy-number profiles and SNP B-allele fraction profiles were
determined using a novel pipeline based on principles from Voet
et al. (22) and Baslan et al. (26).
In order to conduct focal read depth analysis, genomic bins
were first defined by generating artificial reads of a length equal
to the single-cell reads (69 bases after trimming) from every
base in the human genome and mapping them back to the
reference genome using BWA. Reads mapping at multiple loci
were discarded resulting in “uniquely” mappable positions. Subse-
quently, the human genome was divided into non-overlapping
bins of 50 kb unique positions (26) resulting in physical bin
sizes of 51.5 kb on average (1.8 kb SD, when 1% of the top bins
were removed). To each bin’s single-cell read-count a value of
one was added, and bins with a %GC-content of <28% were
discarded. The logR-values for these non-overlapping variable
bins were subsequently computed by dividing the read-count
of a given bin by the average read-count of the bins genome
wide. The logR-values were corrected for %GC-bias using a
Loess fit in R, and were normalized according to the median
of the genome-wide logR-values (Figure 1). Corrected logR-
values were segmented using PCF (the penalty parameter, γ, was
set to 25) (27). Integer DNA-copy number was estimated as
2logR×Ψ, where the average ploidy, Ψ, of the tumor cell was
estimated based on the logR value of a large reference region
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with known DNA-copy number without large copy-number
aberrations (22).
To perform SNP genotyping from the sequencing data, we used
known SNP positions from dbSNP (version 135) and calculated a
SNP BAF for each SNP covered by at least eight reads (22).
COPY-NUMBER ANALYSIS OF PRIMARY TUMORS
Primary tumor DNA was analyzed for copy-number aberrations
using Genome-Wide Human SNP array 6.0 (Affymetrix, Santa
Clara, CA, USA). Raw data was normalized by HapMap using
Affymetrix Power tools and copy-number aberrations were ana-
lyzed using the allele-specific copy-number analysis of tumors
(ASCAT) (30). ASCAT germline prediction was performed for
MicMa003, due to noisy blood SNP-CGH data, while MicMa083
was analyzed with matched germline data. Segmentation of the
data was performed by the allele-specific piecewise constant fit-
ting (asPCF) algorithm (27). SNP-CGH data can be obtained by
contacting the authors.
RESULTS
In this study we have sequenced WGA DNA from two DTCs
(DTC003 and DTC083) derived from the BM of two non-
metastatic breast cancer patients at the time of diagnosis. We have
optimized the sequencing protocol and data analysis for DTCs, as
well as compared copy-number alterations in the single cells and
the corresponding primary tumor.
WHOLE-GENOME SEQUENCING OF DTCs
DTC003 and DTC083 were whole-genome sequenced to 14.5
and 10.45 Gb, respectively. Following mapping and PCR dupli-
cate removal, the attained breadth of coverage was 33.9 and 38.7%
of the human reference genome, while the depth of coverage was
2.92× and 2.03× (when compared to the size of the human ref-
erence genome) and 8.61× and 5.25× (when compared to the
breadth of covered bases), respectively. This allowed us to study
the copy-number landscape in combination with the SNP B-allele
fractions.
COPY-NUMBER ANALYSIS COMPARING WHOLE-GENOME
SEQUENCING TO aCGH
To analyze the copy number changes in the DTCs, logR ratios
were derived from local sequencing depth of the sample using
non-overlapping variable windows (mean size 51.5 kb), without
applying a deep-sequenced reference sample as reported previ-
ously (22), thereby also circumventing logR anomalies induced
by CNVs present in the reference sample. The normalized logR-
values were segmented using PCF and copy-number profiles were
generated (described in detail in Materials and Methods). Results
were compared to previously reported aCGH copy-number analy-
ses of the same DTCs (25). Some differences and similarities of the
two approaches are illustrated in Figure 2, where PCF parameters
were set based on amount of noise in the data. A copy-number
profile derived from non-WGAed DNA extracted from the pri-
mary tumor (see also below) was in addition applied as a control.
DTC003 had a whole-arm amplification of 1q observed by aCGH
and sequencing, which is also present in the non-WGA primary
tumor profile, corroborating its authenticity (Figure 2A). Addi-
tional focal deletions were seen in the sequencing data, but were
not observed in either the DTC aCGH or primary tumor profile.
In contrast, DTC083 (Figure 2B) shows several small deletions
on chromosome 1p, which are endorsed by the MicMa083 profile
(see also Figure 4A), but which are only captured by sequence
data analysis, not by aCGH analysis of the same single-cell WGA-
product. The latter aCGH approach only captures a larger deletion
on 1p and a whole-arm 1q gain in DTC083. Figure 2B also shows a
false positive deletion (indicated with an arrow) on 1p detected in
the aCGH data. Similar findings were seen on other chromosomes
(Figure S1 in Supplementary Material).
COPY-NUMBER ANALYSIS COMPARING WHOLE-GENOME
SEQUENCING OF DTC TO SNP-CGH (SUBCLONE) ANALYSIS OF THE
PRIMARY TUMOR
The two primary tumors (MicMa003 and MicMa083) correspond-
ing to DTC003 and DTC083 were analyzed using SNP-CGH
(Materials and Methods) and their copy-number profiles were
generated using the ASCAT algorithm followed by allele-specific
segmentation by the PCF algorithm (27, 30). Copy-number analy-
sis showed few aberrations in DTC003, including a monosomy 4,
large-scale deletions on chromosomes 6, 16, and 17, and large-
scale amplifications on chromosomes 1 and 17 (Figure 3A). The
primary tumor, MicMa003, showed a SNP-CGH copy-number
profile that is ~99% concordant to the corresponding DTC. No
major subclonal changes at the copy-number level were detected
in the primary tumor by ASCAT (Figure 3B).
Similarly to its corresponding DTC, the more highly aberrant
primary tumor, MicMa083, showed multiple alterations over the
whole genome (Figure 4A). At first glance, the primary tumor
demonstrated a SNP-CGH copy-number profile that was ~89%
concordant to its corresponding DTC. However, when studied
in more detail, the primary tumor copy-number profiles indi-
cated the existence of subclonal changes (Figure 4B), from which
DTC083 likely descents (Figure 4A). For instance a deletion of
one of the alleles of chromosome 13 was observed as subclonal
in the primary tumor, while the DTC had a cnLOH (copy neutral
LOH). Similarly,DTC083 showed a DNA-gain of chromosome 16p
that was observed as subclonal (Figure 4B) in the primary tumor,
while a trisomy 21 in the DTC was not apparent in the primary.
A putative chromothripsis event on chromosome 2 was recapitu-
lated in both the primary tumor and the DTC (Figure 4A). These
clonal and subclonal events provide evidence of a tumor evolution
at the copy-number level. Taken together, these results indicate
that the DTC could be derived from a subclone of the primary
tumor. Figure 5 illustrates animated genomic changes explaining
a possible tumor progression model for MicMa083.
DISCUSSION
Single-cell analyses have become an important tool in analysis
of tumor heterogeneity (7), as well as in detection and charac-
terization of the genomic complexity of CTCs (21) and DTCs.
So far, genomic alterations of DTCs have only been detected by
aCGH and/or FISH methods (24, 25, 31). In this paper, we demon-
strate that whole-genome sequencing of single DTCs is feasible and
may provide information about high-resolution genetic changes,
as well as copy-number neutral events.
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FIGURE 2 | Comparison of copy-number data of DTCs generated from
whole-genome sequencing (middle side) and aCGH (right side), with the
primary tumor as a control (left side). The piecewise constant fitting
algorithm was used to generate segments with gamma=25 and kmin =5 for
the sequencing and primary tumor data, and gamma=60 and kmin =25 for
the aCGH data. (A) DTC003: gain of chromosome 1q was observed with both
technologies, where a focal deletion on 1p was only detected in the DTC
sequencing data, and not recapitulated in either the DTC aCGH or primary
tumor profile. (B) DTC083: copy-number alteration on chromosome 1 shows
that aCGH data do not recapitulate the smaller deletion on the 1p loci,
however both technologies capture the 1q whole-arm amplification. A false
aberration is found in the aCGH data (marked with a black arrow).
In contrast to multi-cell analysis, investigation of genomic
changes in a single cell requires WGA due to the small amount
of DNA acquired from a single tumor cell. Various sequence
biases introduced by WGA have been reported and it may be
difficult to distinguish between the true genomic variation of
the cell and allelic amplification introduced by the amplifica-
tion process (7, 22, 32). Consequently, this can lead to difficulties
in detection and interpretation of true copy-number changes.
Creating non-overlapping, uniquely mapping genomic bins, and
calculating the read count for each bin provided high-resolution
copy-number data following WGA-specific GC-bias adjustment.
In the aCGH analysis by Mathiesen et al. a moving LogR average
was calculated to avoid false aberrations caused by the amplifi-
cation (25). The study demonstrated how single-cell aCGH from
WGA DNA could be used to detect genomic aberrations in DTCs
from BM, however the sparse coverage of the genome, due to
the WGA, resulted in noisy data with a systematic fluctuation in
probe values. Segmentation of the aCGH was also affected by
the noise, making it problematic to interpret the copy number
changes. Larger alterations were detected and validated by FISH,
which were entirely recapitulated in the sequencing data. In
contrast, the sequencing copy-number profiles described here
revealed also smaller rearrangements, as well as copy-number neu-
tral changes. Most of the copy number changes detected with
single-cell sequencing were recapitulated in the integer copy-
number profile obtained with the non-WGAed DNA extracted
from the primary tumor, corroborating their authenticity. Excep-
tions include copy-number aberrations that are subclonal in
origin (see below) and certain focal DNA imbalances, which
could be true changes in the DTC or false positive artifacts
from the WGA, requiring further validation. Calculation of SNP
BAF-values provided the opportunity to examine allele-specific
copy number changes and allowed validating a number of the
DNA imbalances. Additionally, the SNP BAF-values highlighted
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FIGURE 3 | Copy-number changes were analyzed from sequencing
data from the DTC003 and SNP-CGH data from the corresponding
primary tumor, MicMa003. (A) Comparison of aberration pattern in
the DTC and primary depicted by Circos plots. BAF reveals allelic loss
and copy-number alterations of the DTC003 showed ~99%
concordance with its primary tumor. (B) SNP-CGH profile of primary
tumor shows few subclonal alterations. Clonal amplifications and
deletions were observed.
important subclonal changes when comparing DTC with primary
tumor.
Another issue seen in sequencing analysis of WGA products is
obstructed alignment of reads containing true genomic sequence
due to presence of WGA-adapter sequences in the reads. One could
remove WGA-adaptors from amplicons through sonication before
starting sequence library preparation of the cell’s WGA product
(7), but even when using this approach we still detect several
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FIGURE 4 | Copy number changes were analyzed from sequencing
data from the DTC083 and SNP-CGH data from the corresponding
primary tumor, MicMa083. (A) Circos plots reveal aberration pattern
differences between the DTC and primary tumor, with ~89%
concordance in the copy number changes. BAF show cnLOH on
chromosome 13 in the DTC where the primary tumor had a subclonal
deletion. Amplification of chromosome 21 seems to be novel in the DTC.
(B) ASCAT profile of primary tumor describes several subclonal
alterations, such as amplification on chromosome 1q and 16p, and
deletion of chromosome 13.
reads containing adaptor sequence. Thus it is important to trim
off the adaptor sequences using informatic tools, before mapping
single-cell sequence reads back to the human reference genome.
An enzymatic solution to this problem may be developed.
The complexity of the genomic rearrangements was different
between the two primary tumors, where MicMa083 was a highly
aberrant tumor with a higher degree of subclonal changes. Both
the primaries and DTCs showed gain of chromosome 1q, which is
www.frontiersin.org December 2013 | Volume 3 | Article 320 | 7
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FIGURE 5 | A proposed and animated model of how the tumor evolution has occurred in MicMa083 at the copy-number level. Aberrations change from
clonal to subclonal, where the DTC could descend from one of the primary subclones.
known to be a common event in ER positive breast cancers and is
thought to occur at an early stage in tumor development (9, 33).
MicMa003 and the corresponding DTC003 had 99% concordant
copy-number profiles. MicMa003 did not show subclonal changes
of significance and there was no evidence that the DTC had gone
through further evolution at the copy-number level, which could
indicate a less complex tumor progression where the dominating
cell population within the tumor has gained the properties nec-
essary for tumor cell dissemination. In contrast, the more highly
aberrant DTC083 exhibited evidence of further evolution from
its primary tumor. The tumor, MicMa083, had a highly subclonal
copy-number profile and a lower general concordance to DTC083
(89%). In DTC083, cnLOH was observed where MicMa083 had a
deleted copy of chromosome 13, and in addition a gain on chro-
mosome 16p. These findings indicate that DTC083 may derive
from a subclone of the primary that has undergone a subsequent
duplication of the retained chromosome 13, and an allele-specific
gain of 16p. DTC083 revealed trisomy 21, which does not appear
to be subclonal in the primary tumor, and thus, could be a de
novo gain or a small subclone not detected. If de novo, it may be
either a stochastic event or a prerequisite for tumor dissemina-
tion, but a larger study is necessary for stating the relevance of the
observation. Clonal events in the primary tumor were observed
in DTC083, such as a putative chromothripsis (34) event on chro-
mosome 2, as well as deletion and amplification of several other
loci genome wide. These aberrations might be early copy-number
events in tumor evolution. Although genomic changes are known
to be important for tumor progression, they are not always directly
transferrable to gene expression and phenotypic characteristics of
the tumor cells. It is therefore important to develop methods that
preserve the possibility for both DNA and RNA sequencing from
single cells.
Naume et al. (35) found that presence of DTCs in BM resulted
in reduced survival especially for breast cancer patients with
tumors classified as ER positive, luminal A subtype (36). In our
study the two presented patients had ER positive primary tumors
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and developed systemic relapse during follow up. Thus certain
clones from the primary tumors, with quite different genomic
complexity, seemed to be capable of metastasizing. Dissecting the
molecular heterogeneity of the primary tumor and metastasis is
further facilitated through deep sequencing (7, 9). To obtain fur-
ther insight into the genomic pattern and differences between
primary tumor and DTCs in breast cancer, larger number of
patients needs to be analyzed, including all breast tumor subtypes.
Also, higher coverage and investigation of multiple DTCs from the
same patients, as well as their metastases will facilitate the study of
the mechanism behind dissemination and recurrence. The feasi-
bility of the method and analytical approach presented here opens
the possibility to sequence not only the bulk tumor, but also single
tumor cells from BM and blood.
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